The talk will cover inflammatory, neoplastic, and infectious diseases of the face, including periorbital, perioral, and malar geographies. Participants will learn to identify lesions in the context of differential diagnosis and receive an overview of first-line therapeutic approaches. Where applicable, newly approved medications in dermatology will be reviewed (e.g., psoriasis, eczema, and rosacea). Some disease states to be covered include acne, rosacea, allergic contact dermatitis, dermatomyositis, melanoma, basal cell carcinoma, melasma, and sarcoidosis.
Thyroid disorder is a common disorder and it effects all ages. In children, hypothyroidism can delay growth and mental development. In the elderly, thyroid disorders can result in severe hypothyroidism and death due to myxedema coma. All aspects of thyroid disease effects many medical providers. This talk will cover the most common and the most serious conditions that can be caused by abnormalities in thyroid function.
The speaker will illustrate how ADHD manifests in adulthood and explore assessment and management tools. In addition to a deep dive into the complicated interface between stimulant treatment and addiction, participants will learn about old and new stimulants along with behavioral interventions. Understanding mindfulness as a tool for ADHD will help learners make a difference in their patients with ADHD.
Expert faculty discuss how to optimize the use of PCSK9 inhibitors in the management of individuals with coronary heart disease.
This lecture will address management of cigarette-smoking-related lung diseases, chronic bronchitis, and emphysema, and feature prevention (smoking abstinence and smoking cessation) and interventions (pharmacologic and nonpharmacologic). COPD is now the third most common cause of death in the United States. To improve care for their patients with COPD, participants will learn about diagnosing COPD, assessing its severity, and adjusting therapy according to that assessment. The speaker will also touch upon management of acute exacerbations of COPD in the ambulatory setting.
The session will review the latest clinical information regarding cannabis use for medical purposes. Particular attention will be given to the latest information regarding treating inflammatory bowel diseases and neurologic disorders. Pulmonary and cardiovascular risks will be reviewed. The speaker will also discuss marijuana use for the elderly and inform participants about issues related to impaired driving.
Over 40% of men over the age of 50 will suffer from erectile dysfunction (ED) or hypogonadism and these conditions often co-exist in many men. Clinicians should be aware of the new 2018 American Urologic Association (AUA) ED guidelines and how the paradigm of ED treatments has now changed. In addition, over the past 5 years there have been numerous controversies with the diagnosis and management of hypogonadism. Clinicians should be aware of these controversies and should be familiar with the new 2018 AUA and Endocrine guideline on testosterone therapy.
This talk will be aimed for primary care physicians with a goal of understanding and defining CKD as its prevalence continues to rise in the era of hypertension, diabetes and obesity epidemics. The attendant will understand and identify patients at risk and with CKD and the natural course of the disease. They will be supplied with tools clinically proven to slow down progression of the disease and understand the denouement of CKD.
This talk will update participant knowledge about hormone therapy for menopause, focusing on our current understanding of the myths, benefits, and harms of treatment. The myth that hormone therapy is, in general, harmful, is based on data looking at the consequences of hormone therapy in individuals aged 60 and older. In contrast, the data on most individuals who are either under age 60 or less than 10 years from menopause show that the benefits appear to outweigh the risks. A clinical practice guideline published by the Endocrine Society recommends an individualized approach to treatment based on calculating baseline cardiovascular and breast cancer before initiating therapy. The benefits of hormone therapy for menopause include management of hot flashes and vaginal atrophy. It is not recommended for the prevention of cardiovascular disease, osteoporosis, or dementia. In the Women’s Health Initiative combined hormone therapy trial, risks included coronary events, stroke, venous thromboembolism, and breast cancer. No increase in either coronary heart disease or breast cancer risk was seen with unopposed estrogen. These results suggest that the progestin played an important role in the increased coronary and breast cancer risk seen with combined therapy.
In this activity, Dr. Eslami will give an overview of an ambulatory approach to the evaluation and medical management of urinary incontinence by identifying the steps involved for performing a basic evaluation of a patient with urinary incontinence. She will discuss and provide strategies for treatment and explain how treatment can be optimized for each individual patient.
Get your questions answered by expert faculty in Endocrinology. You ask: we listen. You will learn practical solutions to common clinical challenges and tips to apply the latest knowledge in practice.
Anxiety Disorders affect a large portion of our population, are prevalent across cultures and carry a significant degree of disability. I my talk, I will briefly describe the current theoretical models we use to understand anxiety. I will describe in some detail several conditions that fall under the umbrella of anxiety disorders (GAD, social anxiety, and panic disorder) and, in each case, will focus on prevalence, pathogenesis, clinical diagnosis, comorbidities and course. I will finally focus on treatment options, including psychotherapeutic and psychopharmacologic approaches.